A Comparison of Postoperative Surgical Outcomes among Women Undergoing Obstetric Fistula Repair with and without HIV
International Journal of Maternal and Child Health and AIDS (IJMA) · 30.10.2021 · 10 (2) · 191-197
DOI: 10.21106/ijma.509 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Maternal and Child Health and AIDS (IJMA), online erschienen am 30.10.2021. Verfasst von Prakash R Ganesh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Family Medicine and Community Health, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine…. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objective: Obstetric fistula affects approximately 2 million women worldwide, predominantly in places with a high Human Immunodeficiency Virus (HIV) burden. In Malawi, where thousands of women live with fistulas, HIV prevalence is 11-13%. Although repair is usually successful, surgical outcomes among immunocompromised women are poorly understood. Inconsistent guidelines regarding the Cluster of Differentiation 4 (CD4) threshold necessary for repair make it difficult for surgeons to make informed decisions. This study compares the postoperative outcomes of women undergoing obstetric fistula repair with and without HIV, stratified by CD4 count.
Methods
This is a retrospective case-control study using a database of women who underwent vesicovaginal fistula repair at the Fistula Care Center from 2010-2018. HIV-positive participants, stratified by CD4350, were matched to HIV-negative controls by age within 5 years and Goh classification. Controls were matched to cases in a 3:1 ratio. Bivariate analysis and logistic regression were conducted on indicators based on HIV status and CD4 count stratification. Outcomes included dye test results, pad weights, and continence status at 2 weeks post-repair.
Results
54 seropositive women were matched to 135 seronegative women. Of the 54 HIV positive women, 22.2% (n=12) had a CD4 count < 350. We found no statistically significant difference in surgical outcomes between HIV-positive and negative patients. 93.5% of HIV positive and 90% of HIV negative women healed completely. In our sub-analysis of 12 seropositive women with CD4350 can safely undergo obstetric fistula repair. Further research is needed to evaluate postoperative outcomes among women with CD4
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Family Medicine and Community Health, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, USA.
- Lighthouse Trust, Lilongwe, Malawi.
- UC Berkeley-UCSF Joint Medical Program, 533 Parnassus Ave, San Francisco CA 94143, USA.
- Amphia Hospital, Molengracht 21, 4818 CK Breda, The Netherlands.
- Baylor Foundation, Lilongwe, Malawi.
- Urology Institute, Division of Female Sexual Health, University Hospitals Cleveland Medical Center, USA.
Zitieren
APA
Ganesh, P. R., Mernoff, R., Dikkers, R., Nundwe, W., & Pope, R. (2021). A Comparison of Postoperative Surgical Outcomes among Women Undergoing Obstetric Fistula Repair with and without HIV. International Journal of Maternal and Child Health and AIDS (IJMA), 10(2), 191-197. https://doi.org/10.21106/ijma.509
Vancouver
Ganesh PR, Mernoff R, Dikkers R, Nundwe W, Pope R. A Comparison of Postoperative Surgical Outcomes among Women Undergoing Obstetric Fistula Repair with and without HIV. International Journal of Maternal and Child Health and AIDS (IJMA). 2021;10(2):191-197. doi:10.21106/ijma.509
BibTeX
@article{Ganesh2021,
author = {Ganesh, Prakash R and Mernoff, Rachel and Dikkers, Renske and Nundwe, William and Pope, Rachel},
title = {A Comparison of Postoperative Surgical Outcomes among Women Undergoing Obstetric Fistula Repair with and without HIV},
journal = {International Journal of Maternal and Child Health and AIDS (IJMA)},
year = {2021},
volume = {10},
number = {2},
pages = {191--197},
doi = {10.21106/ijma.509}
}
EUVIMED